# Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study

> **NCT07739511** · PHASE1,PHASE2 · RECRUITING · sponsor: **Liu Shu** · enrollment: 30 (estimated)

## Conditions studied

- HER2 + Breast Cancer

## Interventions

- **COMBINATION_PRODUCT:** Paclitaxel oral solution plus Trastuzumab and Pertuzumab

## Key facts

- **NCT ID:** NCT07739511
- **Lead sponsor:** Liu Shu
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-29
- **Primary completion:** 2027-07-31
- **Final completion:** 2029-07-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07739511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07739511, "Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07739511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*